Koers Arrowhead Research Corp Nasdaq
Aandelen
US0427972098
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 126 mln. 117 mln. | Omzet 2025 * | 179 mln. 167 mln. | Marktkapitalisatie | 2,99 mld. 2,78 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -313 mln. -291 mln. | Nettowinst (verlies) 2025 * | -304 mln. -282 mln. | EV/omzet 2024 * | 20,4 x |
Nettoliquiditeiten 2024 * | 426 mln. 396 mln. | Nettoliquiditeiten 2025 * | 313 mln. 291 mln. | EV/omzet 2025 * | 14,9 x |
K/w-verhouding 2024 * |
-8,79
x | K/w-verhouding 2025 * |
-9,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,51% |
Recentste transcriptie over Arrowhead Research Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 01-12-07 | |
Director of Finance/CFO | 57 | 01-01-09 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 23-11-10 |
Michael Perry
BRD | Director/Board Member | 64 | 19-12-11 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 01-09-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,43% | 103 mld. | |
+8,96% | 101 mld. | |
+4,40% | 23,07 mld. | |
-12,15% | 22,23 mld. | |
-4,36% | 18,05 mld. | |
-39,98% | 17,18 mld. | |
-10,04% | 16,94 mld. | |
+6,79% | 14,07 mld. | |
+38,61% | 12,35 mld. |